Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice

Journal of Alzheimer's Disease

Volumn 44, Issue 4, 2015, Pages 1145-1156

  Frederick, Christelle ^a   Ando, Kunie ^a   Leroy, Karelle ^a   Héraud, Céline ^a   Suain, Valérie ^a   Buée, Luc ^b   Brion, Jean Pierre ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

CCI 779; macroautophagy; mTOR; neurofibrillary tangles; tauopathy

Indexed keywords

PROTEIN KINASE B; RAB7 PROTEIN; RAPAMYCIN DERIVATIVE; TAU PROTEIN; TEMSIROLIMUS; PROTEIN KINASE INHIBITOR; RAB PROTEIN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; MACROAUTOPHAGY; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAUOPATHY; TRANSGENIC MOUSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; METABOLISM; MOTOR ACTIVITY; MOVEMENT DISORDERS; MUTATION; PATHOLOGY; ROTAROD TEST;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; GENE EXPRESSION REGULATION; HUMANS; LIVER; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOVEMENT DISORDERS; MUTATION; PROTEIN KINASE INHIBITORS; RAB GTP-BINDING PROTEINS; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; SIROLIMUS; TAU PROTEINS; TAUOPATHIES; TOR SERINE-THREONINE KINASES;

EID: 84923286026     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142097     Document Type: Article

References (47)

1. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95-130.
2. Goedert M, Spillantini MG (2011) Pathogenesis of the tauopathies. J Mol Neurosci 45, 425-431.
3. Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19, 983-997.
4. Rubinsztein DC (2006) The roles of intracellular proteindegradation pathways in neurodegeneration. Nature 443, 780-786.
5. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 16, 46-56.
6. Bove J, Martinez-Vicente M, VilaM (2011) Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat Rev Neurosci 12, 437-452.
7. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, EastonDF, Duden R, O'Kane CJ, RubinszteinDC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36, 585-595.
8. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC (2010) Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 133, 93-104.
9. Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, FeanyMB (2006) TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 16, 230-241.
10. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15, 433-442.
11. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, GoedertM (2012) Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 135, 2169-2177.
12. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8, 609-622.
13. Hosokawa M, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, Akiyama H, Hasegawa M (2012) Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One 7, e52389.
14. Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces Abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21, 140-149.
15. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: Effects on cognitive impairments. J Biol Chem 285, 13107-13120.
16. Majumder S, Richardson A, Strong R, Oddo S (2011) Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 6, e25416.
17. Oddo S (2012) The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) 4, 941-952.
18. Pei JJ, Hugon J (2008) mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med 12, 2525-2532.
19. Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, Branca RM, Lehtio J, Guan Z, Filipcik P, Xu S, Winblad B, Pei JJ (2013) Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: Implication for Alzheimer disease. J Biol Chem 288, 15556-15570.
20. An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ (2003) Up-regulation of phosphorylated/ activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 163, 591-607.
21. Pei JJ, Bjorkdahl C, Zhang H, Zhou X, Winblad B (2008) p70 S6 kinase and tau in Alzheimer's disease. J Alzheimers Dis 14, 385-392.
22. Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT (2013) Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One 8, e62459.
23. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. Aging Cell 12, 370-380.
24. Huang S, Houghton PJ (2001) Mechanisms of resistance to rapamycins. Drug Resist Updat 4, 378-391.
25. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5, 671-688.
26. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R (2010) FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15, 428-435.
27. Pal SK, Quinn DI (2013) Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 39, 709-719.
28. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616.
29. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, Yilmaz Z, Buee L, Brion JP (2007) Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol 171, 976-992.
30. Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178, 803-816.
31. Brion JP, Hanger DP, BruceMT, Couck AM, Flament-Durand J, Anderton BH (1991) Tau in Alzheimer neurofibrillary tangles. N-and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem J 273 (Pt 1), 127-133.
32. OtvosLJr, Feiner L, Lang E, Szendrei GI, GoedertM, LeeVM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39, 669-673.
33. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33, 43-55.
34. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 307, 1098-1101.
35. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65, 391-426.
36. Jager S, Bucci C, Tanida I, Ueno T, Kominami E, Saftig P, Eskelinen EL (2004) Role for Rab7 in maturation of late autophagic vacuoles. J Cell Sci 117, 4837-4848.
37. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19, 5720-5728.
38. Prockop LD, Naidu KA, Binard JE, Ransohoff J (1995) Selective permeability of [3H]-D-mannitol and [14C]-carboxyl-inulin across the blood-brain barrier and bloodspinal cord barrier in the rabbit. J Spinal Cord Med 18, 221-226.
39. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395.
40. Gutierrez MG, Munafo DB, Beron W, Colombo MI (2004) Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J Cell Sci 117, 2687-2697.
41. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22, 9340-9351.
42. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351.
43. Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, Zhang QQ, Shi JQ, Gao L, Qin H, Zhang YD, Tan L (2014) Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacol Res 81C, 54-63.
44. Wyttenbach A, Hands S, King MA, Lipkow K, Tolkovsky AM (2008) Amelioration of protein misfolding disease by rapamycin: Translation or autophagy? Autophagy 4, 542-545.
45. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12, 5755-5763.
46. Buckner JC, Forouzesh B, Erlichman C, Hidalgo M, Boni JP, Dukart G, Berkenblit A, Rowinsky EK (2010) Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest NewDrugs 28, 334-342.
47. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition ofmTORby rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 5, e9979.